Gilteritinib with venetoclax and azacitidine for FLT3-positive AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests adding a targeted drug called gilteritinib to a standard two-drug combination (venetoclax and azacitidine) for people with a specific genetic change (FLT3 mutation) in their acute myeloid leukemia (AML). The goal is to see if the three drugs together work better than the two alone, for patients who cannot tolerate strong chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been newly diagnosed with acute myeloid leukemia (AML), not a relapse or a recurrence.
- Your leukemia cells must have a change in the FLT3 gene (this is tested on your bone marrow sample).
- You cannot take standard strong chemotherapy because of your age or health issues.
- You may have had one cycle of the combination venetoclax and azacitidine (as part of your initial care), but no other AML treatment except hydroxyurea.
- You cannot have any known active spread of leukemia to the brain or spinal cord (CNS).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted therapy that specifically attacks leukemia cells with the FLT3-ITD gene change. If you have this mutation, the goal is to see if adding this drug to standard chemotherapy improves your chances of going into remission.
This trial tests a combination of three chemotherapy drugs (venetoclax, azacitidine, and cytarabine) for people newly diagnosed with acute myeloid leukemia who have never received AML treatment before. The goal is to see if this combination can help patients go into remission and live longer.
This trial compares a new combination treatment to standard chemotherapy plus a targeted drug (called an FLT3 inhibitor) in people with AML that has a FLT3 mutation. The goal is to see if the new approach works better and helps improve outcomes.
This trial is testing a three-drug combination for people newly diagnosed with a type of AML that has a FLT3 mutation. The goal is to see if this treatment works better than standard care.
This trial tests a three-drug combination for people with acute myeloid leukemia (AML) that did not respond to or came back after previous treatment with azacitidine and venetoclax. The goal is to see if adding gilteritinib can help control the leukemia.
This trial tests whether adding an oral chemotherapy pill (azacitidine) to the targeted drug gilteritinib helps people whose FLT3-mutated AML came back or didn't respond after their first treatment. The goal is to see if the combination is more effective than gilteritinib alone.
Hear when a new AML - Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.